The idea of irreversible inhibitors adhering permanently to a target protein has gained increasing attention for application in potential drug development. However, one of many hurdles is the ...
For the first time, scientists have identified promising drug candidates that bind irreversibly with a notoriously undruggable cancer protein target, permanently blocking it. Transcription factors are ...
A first-in-human phase Ia trial reports that the covalent TEAD palmitoylation inhibitor BPI-460372 showed preliminary ...
A review in Biological Research details how telomerase-targeted therapies, including imetelstat and peptide vaccines, are ...
SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE)-- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and ...
At the ongoing meeting of the American Chemical Society in Denver, F. Hoffmann-La Roche Ltd. has reported the discovery of an orally available and brain-penetrant irreversible asparagine-specific ...
Midostaurin: Review of pharmacokinetics (PK) and PK/pharmacodynamic (PD) relationship in AML/MDS patients ...
Researchers from Johnson & Johnson presented the discovery of a novel inhibitor of cyclin-dependent kinase 7 (CDK7), a co-factor that controls transcription by phosphorylating the C-terminal domain of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results